Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

2,174 resultsPage 83 of 182, newest first
  1. FinanceRadisson Continues to Expand Scope of High-Grade Gold Mineralization Beneath the Former O'Brien Gold Mine with New Drill Results Including 68.24 g/t Gold over 6.2 MetresRouyn-Noranda, Quebec, Sept 21, 2026 - Radisson Mining Resources Inc. (TSXV: RDS) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to announce the results of eight new drill holes recently completed at its 100%-owned O'Brien Gold Project ("O'Brien" or the "Project") located in the Abitibi region of Québec. The eight holes form part of two clusters of drill holes based on pilot holes and wedge branches that are serving to delineate an important system of high-grade mineralization in multiple quartz-sulphide-gold veins over a now 1,000-metre vertical interval beneath the former O'Brien Gold Mine. These results are the latest from the Company's ongoing 140,000-metre step-out drill program designed to test the full scope of gold mineralization at the Project. All eight drill holes reported today returned significant gold mineralization. Highlights (Figure 1 and Table 1) include: OB-26-385W5 intersected 68.24 grams per tonne ("g/t") gold ("Au") over 6.20 metres (core lengths) including 384.01 g/t Au over 1.0 metre and including 28.68 g/t Au over 1.0 metre (residual intercept grade of 2.48 g/t Au); OB-26-385W8 intersected 27.27 g/t Au over 3.3 metres including 72.40 g/t Au over 1.2 metres (residual intercept grade of 1.49 g/t Au), and 3.90 g/t Au over 9.3 metres including 6.10 g/t Au over 2.0 metres and including 5.78 g/t Au over 1.2 metres (residual intercept grade of 2.81 g/t Au), and 8.35 g/t Au over 4.0 metres including 16.10 g/t Au over 1.5 metres (residual intercept grade of 3.7 g/t Au); OB-25-378W4 intersected 8.14 g/t Au over 5.50 metres including 11.52 g/t Au over 3.70 metres (residual intercept grade of 1.19 g/t Au); OB-26-385W7 intersected 18.13 g/t Au over 2.0 metres including 34.91 g/t Au over 1.0 metre (residual intercept grade of 1.35 g/t Au); and OB-25-378W5 intersected 3.90 g/t Au over 9.3 metres including 16.84 g/t Au over 1.4 metres (residual intercept grade of 1.60 g/t Au) and 4.00 g/t Au over 4.60 metres. Matt Manson, President and CEO: "Since the beginning of our deep step-out drilling program at O'Brien in late 2024, we have enjoyed consistent success in expanding the scope of mineralization beyond the former mine and the historical mineral resources. Of the 128 drill holes completed during this period,106 have returned drill intercepts with grades and thicknesses consistent with our mineral resources. This is an impressive 83% "hit" rate (Table 2), and we report every hole completed. We continue to see a consistent pattern of high-grade quartz-sulphide-gold veins within broader, mineralized alteration halos. These mineralized zones form parallel vein packages within the host Piché Group rocks, with good continuity across adjacent drill holes and over significant distances. The two clusters of new drill results reported today are delineating the important "O'Brien Mine East" trend at its top, immediately below the former mine workings, and extending it downwards at up to 2 kilometres vertical depth. In our reporting of drill results, as with today's news, we show the grade of the full interval across the mineralized zone (in core lengths at a 1 g/t Au bottom cut-off) and the "including" interval representing the high-grade quartz-sulphide-gold vein within the zone. The intercept's residual grade, which represents grade in the alteration halo, is typically between 1 g/t Au and 4 g/t Au. These patterns are all demonstrated reliably in today's results. O'Brien is clearly a large scale and increasingly predictable gold mineralizing system. Drilling is ongoing with eight rigs active at the Project." Figure 1: Longitudinal Vertical Section and Plan View of Gold Vein Mineralization and Mineral Resources at the O'Brien Gold Project, with Today's Drill Holes Illustrated To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_f60ab4e7747e2ba4_001full.jpg Gold Mineralization at O'Brien Gold mineralizing quartz-sulphide veins at O'Brien occur within a thin band of interlayered mafic volcanic rocks, conglomerates, and porphyritic andesitic sills of the Piché Group occurring in contact with the east-west oriented Larder Lake-Cadillac Break ("LLCB"). Gold, along with pyrite and arsenopyrite, is typically associated with shearing and a pervasive biotite alteration, and developed within multiple Piché Group lithologies and, occasionally, the hanging-wall Pontiac and footwall Cadillac meta-sedimentary rocks. As mapped at the historic O'Brien mine, and now replicated in the modern drilling, individual veins are generally narrow, ranging from several centimetres up to several metres in thickness and are associated with broader, mineralized alteration envelopes. Multiple veins occur sub-parallel to each other, as well as sub-parallel to the Piché lithologies and the LLCB. Individual veins have well-established lateral continuity, with steeply plunging grade shoots developed over significant lengths. The historic O'Brien mine produced over half a million ounces of gold from such veins and shoots at an average grade exceeding 15 g/t Au and over a vertical extent of at least 1,000 metres. Modern exploration has focussed on delineating well-developed vein mineralization below and to the east of the historic mine. Based on the historic data available, it is clear that the former mine was "high-graded", with mining focused on a main central stope and parallel veins identified but left undeveloped. Figure 2: Visible gold in OB-26-385W5 yielding 384.01 g/t Au over 1.0 metre between 1,514.2 metres and 1,515.2 metres, within a broader intercept averaging 68.24 g/t Au over 6.2 Metres between 1,511 metres and 1,517.2 metres To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissonenfiguretwo.jpg Table 1: Assay Results Calculated at a 3 g/t Au Bottom Cut-Off from Drill Holes Published Today To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissontableone.jpg Notes on Calculation of Drill Intercepts: The O'Brien Gold Project Mineral Resource Estimate effective January 31, 2026 utilizes a 2.20 g/t Au bottom cut-off, a US$2,500 gold price, a minimum mining width of 1.2 metres, and a 60 g/t Au upper cap on individual assays. Intercepts presented in Table 1 are calculated with a 3.00 g/t Au bottom cut-off. Sample grades are uncapped. True widths, based on depth of intercept and drill hole inclination, are estimated to be 30-80% of core length. Table 3 presents additional drill intercepts calculated with a 1.00 g/t Au bottom cut-off over a minimum 1.0 metre core length so as to illustrate the frequency and continuity of mineralized intervals within which high-grade gold veins at O'Brien are developed. Lithology Codes: PON-S3: Pontiac Sediments; V3-S, V3-N, V3-CEN: Basalt-South, North, Central; S1P, S3P: Conglomerate and Greywackes; POR-S, POR-N: Porphyry South, North; TX: Crystal Tuff; ZFLLC: Larder Lake-Cadillac Fault Zone. Step-Out Drilling at O'Brien Since the end of 2024, Radisson has been pursuing a program of broad step-outs beneath the historic O'Brien Gold mine and the existing mineral resources designed to test the extent of gold mineralization at the Project. This drilling is accomplished with pilot holes followed by wedges and directional drilling to maximize drill efficiency and minimize costs. In October 2025, Radisson announced the expansion of the step-out drill program to 140,000 metres employing eight drill rigs (see Radisson news release dated October 16, 2025). The origin of the step-out drill program was the deep pilot hole OB-24-337, which was the first exploration drill hole located below the former mine workings since mining ended in 1957. This hole intersected 31.24 g/t Au over 8.0 metres, including 242.0 g/t Au over 1.0 m at approximately 1,500 metres vertical depth (see Radisson news release dated December 16, 2024). Fifteen wedge branches were completed from OB-24-337 delineating up to eight gold-bearing veins over a 250-metre by 700-metre area in what is referred to as "O'Brien Mine East" (see Radisson news release dated February 12, 2026). In March 2026, Radisson published an interim update in the Project's mineral resources, showing meaningful growth based on the on-going drilling (see Radisson news release dated March 2, 2026). The focus of the step-out drill program has been the extension of mineralization at depth, with an exploration floor of 2 kilometres depth, and recently announced plans to extend this drilling to 2.5 kilometres depth (see Radisson news release dated May 28, 2026). Given the character of neighbouring gold deposits and the wealth of mining infrastructure within or close to the O'Brien Gold Project, Radisson believes that significant exploration potential exists to these depths, and such mineralization might reasonably be expected to be developed. Drilling has recently confirmed the extension of the "Trend 1" zone of mineralization to 1.9 kilometres vertical depth (see Radisson news release dated April 30, 2026). In addition to the progressively deeper drilling, the 140,000-metre program includes targeting of areas within the O'Brien geological model that have not previously been tested and offer the potential for additional mineral resources at shallower depths. Positive drill results have recently been reported from the "Trend 1-Trend 2 Gap" at approximately 500 and 1,000 metres vertical depth, demonstrating continuity of mineralization across what were previously thought to be discrete mineralization trends (see Radisson news release dated June 1, 2026 and September 2, 2026). The eight new drill holes at the Project reported today continue to demonstrate the very high incidence of intercepts with grades and thicknesses consistent with the Project's mineral resources ("hits", per Table 2). This now stands at 83% of all drill holes completed to date, an impressive result for a step-out drill program specifically targeting non-resource areas (Figure 4). Mineralization remains open in every direction, with clear opportunities to expand the quantity of new mineral resources, in particular by drilling at depth. Figure 3: Vertical Section Through "O'Brien Mine East" with Today's New Drill Results To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissonfigurethree.jpg Figure 4: Deep Step-Out Drill Holes Completed and/or Published by the Company Since March 2026 To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_f60ab4e7747e2ba4_008full.jpg Table 2: Drill Results Published for the O'Brien Gold Project Since December 2024 Date of PublicationTotal Number of Drill HolesDrill Holes with Intercepts >+3g/tSuccess Rate (%) September 21, 202688100% September 2, 202666100% July 7, 202633100% June 22, 2026-O'Brien55100% June 22, 2026-Thompson-Cadillac2150% June 1, 20267686% April 30, 2026-O'Brien77100% April 30, 2026-Thompson-Cadillac9222% January 27, 202677100% January 6, 20266583% October 28, 2025151387% September 8, 2025151387% July 16, 2025141179% April 2, 202533100% February 26, 2025201575% December 16, 202411100% Total12810683% Table 3: Detailed Assay Results Calculated at a 1 g/t Au Bottom Cut-Off from Drill Holes Published Today (see "Notes on Calculation of Drill Intercepts") To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissontablethree.jpg To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissontablethreeb.jpg To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissontablethreec.jpg Table 4: Drill Hole Collar Information for Drill Holes Published Today To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10977/315120_radissontablefour.jpg Notes: Hole lengths for wedges represent meterage from point of wedge. Collar position is reported for pilot hole. QA/QC All drill core in this campaign is NQ in size. Assays were completed on sawn half-core, with the second half retained in the core box for future reference. Geologists mark cut lines on the core perpendicular to the foliation. The half on the right side of the saw blade is bagged for the laboratory and the left half is retained as reference. Sample bags are sealed, placed in rice sacks, plastic-wrapped on pallets, and held in a secure facility until pick-up by the laboratory's dedicated truck. Samples are delivered to MSALABS' analytical laboratory in Val-d'Or, Québec, for preparation and gold analysis. The entire sample is dried and crushed (70% passing a 2-millimetre sieve) and split to 500 g. Gold analysis is performed on an approximately 500 g aliquot (a single jar) using Chrysos PhotonAssay technology. Mineralized zones containing visible gold, plus additional intervals selected at the discretion of the logging geologist, are analyzed to extinction, whereby the entire sample is split into multiple ~500 g jars, each jar is analyzed by PhotonAssay, and the weighted average of the results is used for reporting. A one-metre sample typically requires five jars. Certified reference materials (CRMs), blank samples, and reject duplicates are inserted for quality assurance and quality control. Either a CRM, a blank, or a duplicate is inserted during regular sampling at a rate of 1 per 25 samples, with the insertion rate increased for intervals selected for assay to extinction. Four different CRMs are in use with an appropriate range of certified grades suited for O'Brien mineralization. Jars of CRM material are stored at the laboratory and inserted into the sample stream as directed by Radisson. The CRMs were selected by Radisson in accordance with Chrysos Corporation's best-practice guidelines for PhotonAssay. Blanks consist of commercially obtained crushed quartzite known to be barren of gold. Samples returning results greater than 1 g/t Au are also fire assayed. MSALABS operates under ISO/IEC 17025 accreditation, utilizing industry-standard QA/QC frameworks for gold analysis. Through the integration of blanks, duplicates, and CRMs into its workflow, the laboratory adheres to established benchmarks that ensure precise, reliable, and verifiable results. QP Disclosure Disclosure of a scientific or technical nature in this news release was prepared under the supervision of Mr. Richard Nieminen, P.Geo, (QC), a geological consultant for Radisson and a Qualified Person for purposes of NI 43-101. Mr. Luke Evans, M.Sc., P.Eng., ing, of SLR Consulting (Canada) Ltd., is the Qualified Person responsible for the preparation of the MRE at O'Brien. Each of Mr. Nieminen and Mr. Evans is independent of Radisson and the O'Brien Gold Project. About Radisson Mining Radisson is a gold exploration company focused on its 100% owned O'Brien Gold Project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec. A July 2025 PEA described a low cost and high value project with an 11-year mine life and significant upside potential based on the use of existing regional infrastructure. Indicated Mineral Resources are estimated at 0.63 Moz (3.49 Mt at 5.59 g/t Au), with additional Inferred Mineral Resources estimated at 1.69 Moz (10.37 Mt at 5.08 g/t Au). Please see the NI 43-101 "O'Brien Gold Project Technical Report and Preliminary Economic Assessment, Québec, Canada" effective June 27, 2025, Radisson's news release dated March 2, 2026 "With Step-Out Drilling Continuing, Radisson Demonstrates Meaningful Resource Growth at O'Brien with an Updated Mineral Resource Estimate" and other filings made with Canadian securities regulatory authorities available at www.sedarplus.ca for further details and assumptions relating to the O'Brien Gold Project. For more information on Radisson, visit our website at www.radissonmining.com or contact: Matt Manson President and CEO 416.618.5885 [email protected] Kristina Pillon Manager, Investor Relations 604.908.1695 [email protected] Forward-Looking Statements This news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates, projections, and interpretations as at the date of this news release. Forward-looking statements including, but are not limited to, statements with respect to the ability to execute the Company's plans relating to the O'Brien Gold Project as set out in the Preliminary Economic Assessment; the Company's ability to complete its planned exploration and development programs; the absence of adverse conditions at the O'Brien Gold Project; the absence of unforeseen operational delays; the absence of material delays in obtaining necessary permits; the price of gold remaining at levels that render the O'Brien Gold Project profitable; the Company's ability to continue raising necessary capital to finance its operations; the ability to realize on the mineral resource and mineral reserve estimates; assumptions regarding present and future business strategies; local and global geopolitical and economic conditions and the environment in which the Company operates and will operate in the future; planned and ongoing drilling; the significance of drill results; the ability to continue drilling; the impact of drilling on the definition of any resource; and the ability to incorporate new drilling in an updated technical report and resource modelling; the Company's ability to grow the O'Brien Gold Project; and the ability to convert inferred mineral resources to indicated mineral resources. Any statement that involves discussions with respect to predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "interpreted", "management's view", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. Except for statements of historical fact relating to the Company, certain information contained herein constitutes forward-looking statements. Forward-looking information is based on estimates of management of the Company, at the time it was made, involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the companies to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others; the risk that the O'Brien Gold Project will never reach the production stage (including due to a lack of financing); the Company's capital requirements and access to funding; changes in legislation, regulations and accounting standards to which the Company is subject, including environmental, health and safety standards, and the impact of such legislation, regulations and standards on the Company's activities; price volatility and availability of commodities; instability in the global financial system; the effects of high inflation, such as higher commodity prices; the risk of any future litigation against the Company; changes in project parameters and/or economic assessments as plans continue to be refined; the risk that actual costs may exceed estimated costs; geological, mining and exploration technical problems; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; risks relating to the drill results at O'Brien; the significance of drill results; and the ability of drill results to accurately predict mineralization. Although the forward-looking information contained in this news release is based upon what management believes, or believed at the time, to be reasonable assumptions, the parties cannot assure shareholders and prospective purchasers of securities that actual results will be consistent with such forward-looking information, as there may be other factors that cause results not to be as anticipated, estimated or intended, and neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking information. The Company believes that this forward-looking information is based on reasonable assumptions, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. The Company does not undertake, and assumes no obligation, to update or revise any such forward-looking statements or forward-looking information contained herein to reflect new events or circumstances, except as may be required by law. These statements speak only as of the date of this news release. Please refer to the "Risks and Uncertainties Related to Exploration" and the "Risks Related to Financing and Development" sections of the Company's Management's Discussion and Analysis dated April 23, 2026 for the year ended December 31, 2025 available electronically on SEDAR+ at www.sedarplus.ca. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
  2. FinanceMerckMerck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in JapanRAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer
  3. FinanceAssessment of Europe's Food Waste Recycling Market 2026-2036 Featuring Veolia Environnement, SUEZ Group, Biffa Group, Renewi, BTS Biogas and Other Key PlayersCompanies: Veolia"Europe Food Waste Recycling Market Size, Share & Trends Analysis - Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering. According to the research report, the Europe food waste recycling market is projected to reach $5.91 billion by 2036, at a CAGR of 13.5% during the forecast period 2026-2036. The report provides an in-depth analysis of the Europe food waste recycling market, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by stringent EU waste management regulations and mandatory bio-waste separation policies, rising demand for renewable energy and organic fertilizers, the expanding circular economy agenda across European nations, and increasing adoption of advanced recycling technologies such as anaerobic digestion. Moreover, growing investment in biorefinery infrastructure, the surging demand for bioplastics and bio-based materials, and digital transformation of waste management operations are expected to support the market's growth. However, high upfront capital requirements for recycling infrastructure, feedstock contamination issues, and fragmented regulatory frameworks across EU member states may restrain market growth. The key players operating in the Europe food waste recycling market are Veolia Environnement SA (France), SUEZ Group (France), Biffa Group Limited (U.K.), Renewi plc (Netherlands/U.K.), BTS Biogas Srl/GmbH (Italy), Anaergia Inc. (Canada), WELTEC BIOPOWER GmbH (Germany), PreZero International GmbH (Germany), FCC Environment Ltd (U.K.), Remondis SE & Co. KG (Germany), Biogen (U.K.), ReFood GmbH & Co. KG (Germany), Masias Recycling (Spain), Ecofast Italia (Italy), and others. The Europe food waste recycling market is segmented by byproduct type (organic fertilizers, animal feed, biofuels, bioplastics, and other biochemicals), feedstock source (household food waste, food processing industry, food service and hospitality, retail and supermarkets, and agricultural residues), recycling method (anaerobic digestion, composting, pelletization, fermentation, and other technologies), end-use application, and country. The study also evaluates industry competitors and analyzes the market at the country level. Based on byproduct type, the organic fertilizers segment is expected to account for the largest share of the Europe food waste recycling market in 2026. This segment leads primarily due to the continent's strong commitment to sustainable agriculture, the EU Farm to Fork Strategy targeting 25% organic farmland by 2030, and reduced reliance on chemical fertilizers across European agricultural operations. Food waste-derived compost and digestate fertilizers provide nutrient-rich alternatives to synthetic inputs and are increasingly sought after by farmers and gardeners throughout Europe. The growing emphasis on soil health, carbon sequestration, and biodiversity restoration further underpins demand for organic fertilizers derived from recycled food waste. Regulatory frameworks mandating separate bio-waste collection at the household level ensure a consistent and high-quality feedstock base for organic fertilizer production. Additionally, long-term offtake agreements between major retailers such as Tesco, Carrefour, and REWE with recycling operators provide supply chain certainty and support the development of large-scale composting and digestion facilities across the region. Based on recycling method, the anaerobic digestion segment is expected to account for the largest share of the Europe food waste recycling market in 2026. Anaerobic digestion dominates the European food waste recycling market with a 30-40% share, driven by its ability to simultaneously generate two high-value outputs: renewable biogas (or biomethane) for energy use and nutrient-rich digestate for agricultural applications. This dual-output capability makes anaerobic digestion economically attractive and aligns with both the EU's renewable energy targets under RED III and its circular economy objectives. The technology processes over 35 million tonnes of food waste annually across Europe, generating renewable energy sufficient to power approximately 4 million homes. Countries such as Germany, France, and the Netherlands are leading the deployment of large-scale anaerobic digestion plants, with Germany's national biomethane strategy targeting 10% of its gas grid supplied by food waste and agricultural residues by 2030. Advances in biogas upgrading, decentralized digestion systems, and improved methane yields are expanding the accessibility of this technology to smaller municipalities and rural regions, reinforcing the segment's market dominance. Based on feedstock source, the food processing industry segment is expected to account for the largest share of the Europe food waste recycling market in 2026. The food processing industry dominates feedstock supply with a 40-45% share, supported by consistent and large-volume waste streams from meat, dairy, bakery, and beverage processing operations. Unlike household food waste, which can be subject to contamination from non-organic materials, food processing waste is typically well-sorted and suitable for high-efficiency recycling operations. Producer responsibility schemes and long-term recycling contracts signed between food processors and waste management companies ensure stable feedstock supplies for recycling facilities across Europe. Increasing regulatory pressure on food manufacturers to divert organic waste from landfills, combined with the economic incentive of cost-effective waste disposal through recycling partnerships, is driving this segment's dominance. Innovations in valorization technologies that extract bio-based chemicals, enzymes, and specialty ingredients from food processing residues are also opening new revenue streams and further incentivizing industrial participation in food waste recycling. A thorough geographic analysis of the industry gives detailed insights across key European countries. Germany is expected to account for the largest share of the Europe food waste recycling market in 2026. Germany's leadership in the European food waste recycling market reflects the country's world-renowned waste management infrastructure, mature regulatory frameworks, and strong circular economy culture. Germany's national biomethane strategy, backed by a EUR 3 billion subsidy program, is accelerating the upgrading of anaerobic digestion facilities and driving large-scale food waste valorization. Major waste management companies including Remondis, Veolia, and SUEZ operate extensive processing networks throughout Germany, offering comprehensive services spanning collection, anaerobic digestion, composting, and bio-based product marketing. Western Europe overall leads the regional market, supported by well-established waste collection systems, advanced processing infrastructure, and strong regulatory compliance. In contrast, Eastern Europe is the fastest-growing sub-region, with Poland projected to expand at a 14.4% CAGR, driven by EU funding and rapid infrastructure development. Italy stands out for its circular economy approach, processing 7.1 million tonnes of organic waste annually through over 400 facilities, while France is growing at a 10.6% CAGR, supported by strict anti-waste legislation and a national pact involving over 500 companies committed to halving food waste by 2030. Key Questions Answered in the Report:
  4. AIGlobal Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key PlayersCompanies: DexcomGarmin Ltd.Medtronic plcRoche HoldingSamsung Electronics"Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, and the increasing adoption of personalized healthcare solutions. Wearable biosensors are sophisticated devices that enable real-time tracking of physiological parameters, providing critical data for early disease detection and remote patient management. The global wearable biosensors market is undergoing a profound structural transformation as the healthcare industry shifts from episodic, clinic-based care toward continuous, proactive health management. This evolution is being catalyzed by the rapid miniaturization of sensing technologies and the integration of advanced data analytics and artificial intelligence into consumer wearables. The industry is witnessing a significant transition from simple activity trackers toward medical-grade diagnostic devices that can monitor complex biomarkers like glucose, blood pressure, and cardiac rhythms with high precision. Furthermore, the integration of wearable biosensors with digital health and telemedicine platforms is creating a seamless ecosystem for remote patient monitoring and virtual care delivery. This dynamic shift ensures sustained demand for non-invasive, user-friendly sensing solutions that empower individuals and healthcare providers with actionable health insights, ultimately improving clinical outcomes and reducing healthcare costs. Market Segmentation The global wearable biosensors market is segmented by biomarker type (glucose monitoring, heart rate and cardiac biomarkers, blood oxygen [SpO2] monitoring, blood pressure monitoring, lactate and performance biomarkers, and other biomarkers), product type/form factor (smartwatches, fitness bands, continuous glucose monitoring devices, wearable ECG monitors, smart patches, smart rings, and smart clothing), application (clinical and medical, fitness and wellness, and sports and performance monitoring), end-user (hospitals and clinics, home care settings, fitness and sports organizations, individual consumers, and research institutions), and geography. The study evaluation includes industry competitors and analyzes the market at the country level. Based on Biomarker Type By biomarker type, the glucose monitoring segment is expected to hold the largest share of the global wearable biosensors market in 2026. This dominance is attributed to the high and rising prevalence of diabetes globally and the widespread adoption of continuous glucose monitoring (CGM) systems that eliminate the need for frequent finger-prick testing. Conversely, the heart rate and cardiac biomarkers segment is projected to register significant growth, driven by the increasing integration of ECG and heart rate variability (HRV) sensing into consumer smartwatches, enabling early detection of arrhythmias and other cardiovascular conditions. Furthermore, the lactate and multi-analyte biosensors segments are projected to register the highest CAGR during the forecast period, fueled by the growing demand for performance optimization in sports and the development of non-invasive sensors for comprehensive metabolic health tracking. Based on Product Type / Form Factor By product type/form factor, the smartwatches with integrated biosensors segment is expected to hold the largest share of the global wearable biosensors market in 2026. Smartwatches have become the primary platform for health monitoring due to their high consumer acceptance, multi-functionality, and the continuous addition of medical-grade sensors by leading tech companies. Meanwhile, the continuous glucose monitoring devices segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the shift toward proactive diabetes management and the expansion of CGM use among non-insulin-dependent patients and health-conscious individuals. Additionally, smart patches and smart rings are emerging as high-growth segments, offering discrete and specialized monitoring for clinical and wellness applications. Based on Application By application, the clinical and medical segment is expected to hold the largest share in 2026. The increasing use of wearable biosensors for chronic disease management, post-operative monitoring, and clinical trials drives this segment's leadership. Within this segment, remote patient monitoring (RPM) is a major growth catalyst. Conversely, the fitness and wellness segment is projected to register a steady growth rate, driven by the increasing consumer focus on preventive health and the popularity of activity and sleep tracking. The sports and performance monitoring segment is also witnessing rapid expansion as professional athletes and fitness enthusiasts adopt biosensors to optimize training and recovery through data-driven insights. Based on End-User By end-user, the hospitals and clinics segment is expected to hold the largest share in 2026, reflecting the primary role of healthcare providers in prescribing and managing medical-grade wearable sensors for patient care. Conversely, the home care settings segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the global trend toward decentralized healthcare and the increasing preference for monitoring patients in their home environments to improve comfort and reduce hospital readmissions. The individual consumers segment also remains significant, as more people purchase wearables for personal health and fitness tracking. Geographic Analysis In 2026, North America is expected to account for the largest share of the global wearable biosensors market. The region's leadership is underpinned by a highly advanced healthcare infrastructure, high levels of digital health literacy, and the presence of industry leaders such as Abbott, Dexcom, Apple, and Medtronic in the United States. Furthermore, the early adoption of remote patient monitoring and a favorable reimbursement landscape for digital health technologies contribute to the market's dominance. Key companies in the North America market include Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Apple Inc. (U.S.), Medtronic plc (Ireland), Garmin Ltd. (U.S.), Google LLC (Fitbit - U.S.), Masimo Corporation (U.S.), VitalConnect, Inc. (U.S.), and Biolinq Inc. (U.S.). Asia-Pacific is projected to witness the fastest growth during the forecast period. This expansion is primarily driven by increasing healthcare expenditure, the rapid expansion of the middle-class population, and the high penetration of smartphones and wearable devices in China, India, and Japan. Furthermore, the rising burden of chronic diseases in the region and government initiatives to promote digital health are significant catalysts. Key companies in the Asia-Pacific market include Samsung Electronics Co., Ltd. (South Korea) and various emerging local MedTech startups. Europe remains a critical market for wearable biosensors, characterized by a strong focus on preventive healthcare and the implementation of robust medical device regulations. European countries are increasingly adopting wearable sensors to address the healthcare needs of an aging population and to improve the efficiency of public health systems. The region's focus on data privacy and security is driving the demand for sensors that comply with strict GDPR and MDR standards. Key companies in the Europe market include F. Hoffmann-La Roche Ltd. (Switzerland), Oura Health Ltd. (Finland), and Empatica Inc. (U.S./Italy). Latin America is an emerging market for wearable biosensors, driven by the modernization of healthcare facilities and the increasing adoption of consumer health technologies in Brazil and Mexico. The region is seeing a shift toward more accessible health monitoring solutions as enterprises and individuals seek to manage chronic conditions more effectively. The Middle East & Africa region is experiencing growing interest in wearable biosensors as part of national digital health transformation strategies, particularly in the UAE and Saudi Arabia. Investments in high-tech healthcare infrastructure and the adoption of AI-driven health solutions are expected to be major drivers of market growth in the region. Key Players The key players operating in the global wearable biosensors market include:
  5. HealthcareGrünenthal GroupGrünenthal acquires cancer treatment Stivarga®Latest step in Grünenthal's strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic...
  6. HealthcareThiogenesis Therapeutics, Corp.Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate UpdateThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.Meeting...
  7. HealthcareBeacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)Beacon Therapeutics, a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced positive topline results for its registration-enabling VISTA trial evaluating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).
  8. HealthcareCosmo Pharmaceuticals N.V.Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical PracticeCosmo N.V. (SIX: CMHC) (FSE: C43) ("Cosmo") today announced the results from its CADeNCE study. The study, led by Dominitz et al. and published in Gastroenterology, is the largest cluster-randomised quality improvement study of computer-aided detection (CADe) in colonoscopy. It analysed more than 334,000 procedures performed under routine clinical conditions by 816 endoscopists across 139 U.S. Veterans Health Administration...
  9. SaaSBloomsbury MoneyBloomsbury Money Group appoints ex-SAP engineer as CTO to head global banking platformCompanies: SAPBloomsbury Money Group today announced the appointment of Thomas Holst as Chief Technology Officer. Holst joins from SAP's health technology ecosystem, and brings more than a decade of experience building data-intensive,...
  10. HealthcareESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment OptionHONG KONG, Sept 21, 2026 - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026. CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. The drug was approved by the National Medical Products Administration (NMPA) of China in September 2026, for the conversion of acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults. According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64% of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life. Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management. For patients experiencing recurrent PSVT episodes, further data from studies of CARDAMYST(R) provide additional clinical support. The NODE-302 study evaluated patients with recurrent PSVT episodes during long-term follow-up. Across a total of 188 episodes, the overall conversion rate within 30 minutes was 60.2%, with a median time to conversion of 15.5 minutes and a cumulative conversion rate of 75.1% within 60 minutes. The conversion rate showed a numerical upward trend across multiple episodes. A patient’s response to the first episode was predictive of the response to subsequent episodes, with no evidence of diminished response with repeated use. In a patient-reported outcomes (PRO) analysis from the NODE-303 study, CARDAMYST(R) not only converted heart rhythm but also helped alleviate feelings of a racing or pounding heart and ease anxiety, with patients reporting sustained reductions from baseline in anxiety and stress related to future PSVT episodes. CARDAMYST(R) addresses the critical unmet need for acute self-treatment during PSVT episodes. By reducing the sense of losing control, it shifts the treatment focus from mere disease control to enhancing the overall patient experience. In December 2025, CARDAMYST(R) was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults. CARDAMYST(R) is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. An estimated 3 to 6 million people in China are living with PSVT. Research presented at ESC Congress 2026 further highlights the quality-of-life burden experienced by patients between episodes, while CARDAMYST(R) offers an out-of-hospital, self-administered treatment option for acute episodes. As Everest Medicines’ first approved innovative therapy in the cardiovascular disease field, CARDAMYST(R) complements the Company’s existing portfolio and has the potential to benefit more than 12 million patients in China, including those with PSVT and atrial fibrillation with AFib-RVR.
  11. HealthcareESC 2026最新研究揭示PSVT疾病负担 云顶新耀星必妥(R)填补院外“应急自救”空白香港, 2026年9月21日 - (亚太商讯) - 近日，一项关于阵发性室上性心动过速（PSVT）在发作间歇期对患者日常生活及生活质量影响的纵向研究结果在2026年欧洲心脏病学会年会（ESC Congress 2026）电子壁报专场公布，研究摘要题为“The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”。针对PSVT这一心血管疾病，云顶新耀于今年3月引进星必妥(R)（艾曲帕米鼻喷雾剂），获得其在大中华区的独家开发、商业化及产品地产化权益，进一步充实公司心血管产品管线。 作为一款新型、速效的钙离子通道阻滞剂，星必妥(R)采用便携式鼻喷雾剂给药，具备快速起效、便捷给药的特点，是目前唯一可由PSVT患者在症状发作时自行给药并实现快速终止发作的药物。该药于2026年9月获中国国家药品监督管理局（NMPA）批准，用于治疗成人阵发性室上性心动过速（PSVT）急性症状发作，转复为窦性心律。 临床数据显示，星必妥(R)最早可于给药后5分钟开始起效，30分钟转复率64%，半数患者17分钟内恢复平稳心跳，总体耐受性良好，不良反应轻微，显著减少了对额外急救医疗干预的需求，填补了中国PSVT患者急性发作时院外“应急自救”的空白。星必妥(R)以“自救复律，一喷即妥”的市场定位，赋予PSVT患者自主掌控心律、掌控生活的能力，有望推动PSVT急性发作治疗模式从院内被动急救到患者主动自救的模式革新，缓解患者发作时的焦虑状态、减少急诊就诊和疾病负担，进一步改善患者的长期疾病管理和生活质量。 此次ESC年会上公布的研究显示，PSVT是一种持续影响患者生活质量的慢性疾病，而不仅仅是一种偶发性急症——其对患者生活的影响远远不止发作当时，在两次发作之间也会持续影响生活质量，包括生活方式的改变、日常活动受限、焦虑、睡眠障碍以及对日常工作的影响。因此，除急性期治疗及后续导管消融外，如何在发作时获得及时、便捷的治疗，也是PSVT疾病管理需要关注的方面。 针对PSVT反复发作场景，星必妥(R)的研究进一步提供了数据支持。这些数据表明，其临床价值不仅体现在单次急性发作的快速转复，更在于其对患者长期疾病管理的持续改善。NODE-302研究针对长期随访中反复发作PSVT人群开展探索，在共计188次发作事件中，治疗30分钟内整体转复率达60.2%，中位转复时间15.5分钟，60分钟累计转复率75.1%，且多次发作场景下转复率数值呈上升趋势，个体对药物应答具有一致性，首次应答可预测后续发作的应答，无药物耐受衰减。NODE-303研究患者报告结局（PRO）分析中，星必妥(R)在转复心律的同时，有助于减轻心慌心悸、平复焦虑情绪，患者对未来PSVT发作产生的焦虑和压力水平较基线持续下降。该药填补了PSVT患者急性发作时应急自救的治疗空白，为优化PSVT疾病临床处置模式、提升患者疾病自我管理水平提供了全新治疗工具，帮助患者减少疾病带来的失控感，实现从疾病控制向患者体验提升的转变。 此前，星必妥(R)已于2025年12月获得美国食品药品监督管理局（FDA）批准，成为30多年来首款且唯一获批用于成人PSVT急性症状发作治疗的创新疗法。目前，星必妥(R)还在开发伴有快速心室率反应的房颤（AFib-RVR）适应症，II期ReVeRA研究已取得积极结果，接受艾曲帕米治疗的患者中，58.3%的患者心室率降至每分钟100次以下，而安慰剂组为4%，相关适应症计划推进III期临床研究。 目前，中国PSVT患者约有300万至600万。此次ESC研究进一步呈现了PSVT患者在发作间歇期面临的生活质量负担，而星必妥(R)则针对急性发作场景提供了院外应急自救的治疗选择。作为云顶新耀在心血管疾病领域首个获批的创新药物，星必妥(R)将与该公司现有产品布局形成协同效应，未来有望惠及包括PSVT和伴有快速心室率反应的房颤（AFib-RVR）患者在内的超过1,200万中国患者。 Copyright 2026 亚太商讯. All rights reserved. www.acnnewswire.com
  12. HealthcareESC 2026最新研究揭示PSVT疾病負擔 雲頂新耀星必妥(R)填補院外「應急自救」空白香港, 2026年9月21日 - 近日，一項關於陣發性室上性心動過速（PSVT）在發作間歇期對患者日常生活及生活質量影響的縱向研究結果在2026年歐洲心髒病學會年會（ESC Congress 2026）電子壁報專場公佈，研究摘要題為「The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes」。針對PSVT這一心血管疾病，雲頂新耀於今年3月引進星必妥(R)（艾曲帕米鼻噴霧劑），獲得其在大中華區的獨家開發、商業化及產品地產化權益，進一步充實公司心血管產品管線。 作為一款新型、速效的鈣離子通道阻滯劑，星必妥(R)采用便攜式鼻噴霧劑給藥，具備快速起效、便捷給藥的特點，是目前唯一可由PSVT患者在症狀發作時自行給藥並實現快速終止發作的藥物。該藥於2026年9月獲中國國家藥品監督管理局（NMPA）批准，用於治療成人陣發性室上性心動過速（PSVT）急性症狀發作，轉複為竇性心律。 臨床數據顯示，星必妥(R)最早可於給藥後5分鐘開始起效，30分鐘轉複率64%，半數患者17分鐘內恢複平穩心跳，總體耐受性良好，不良反應輕微，顯著減少了對額外急救醫療幹預的需求，填補了中國PSVT患者急性發作時院外「應急自救」的空白。星必妥(R)以「自救複律，一噴即妥」的市場定位，賦予PSVT患者自主掌控心律、掌控生活的能力，有望推動PSVT急性發作治療模式從院內被動急救到患者主動自救的模式革新，緩解患者發作時的焦慮狀態、減少急診就診和疾病負擔，進一步改善患者的長期疾病管理和生活質量。 此次ESC年會上公布的研究顯示，PSVT是一種持續影響患者生活質量的慢性疾病，而不僅僅是一種偶發性急症——其對患者生活的影響遠遠不止發作當時，在兩次發作之間也會持續影響生活質量，包括生活方式的改變、日常活動受限、焦慮、睡眠障礙以及對日常工作的影響。因此，除急性期治療及後續導管消融外，如何在發作時獲得及時、便捷的治療，也是PSVT疾病管理需要關注的方面。 針對PSVT反覆發作場景，星必妥(R)的研究進一步提供了數據支持。這些數據表明，其臨床價值不僅體現在單次急性發作的快速轉複，更在於其對患者長期疾病管理的持續改善。NODE-302研究針對長期隨訪中反複發作PSVT人群開展探索，在共計188次發作事件中，治療30分鐘內整體轉複率達60.2%，中位轉複時間15.5分鐘，60分鐘累計轉複率75.1%，且多次發作場景下轉複率數值呈上升趨勢，個體對藥物應答具有一致性，首次應答可預測後續發作的應答，無藥物耐受衰減。NODE-303研究患者報告結局（PRO）分析中，星必妥(R)在轉複心律的同時，有助於減輕心慌心悸、平複焦慮情緒，患者對未來PSVT發作產生的焦慮和壓力水平較基線持續下降。該藥填補了PSVT患者急性發作時應急自救的治療空白，為優化PSVT疾病臨床處置模式、提升患者疾病自我管理水平提供了全新治療工具，幫助患者減少疾病帶來的失控感，實現從疾病控制向患者體驗提升的轉變。 此前，星必妥(R)已於2025年12月獲得美國食品藥品監督管理局（FDA）批准，成為30多年來首款且唯一獲批用於成人PSVT急性症狀發作治療的創新療法。目前，星必妥(R)還在開發伴有快速心室率反應的房顫（AFib-RVR）適應症，II期ReVeRA研究已取得積極結果，接受艾曲帕米治療的患者中，58.3%的患者心室率降至每分鐘100次以下，而安慰劑組為4%，相關適應症計劃推進III期臨床研究。 目前，中國PSVT患者約有300萬至600萬。此次ESC研究進一步呈現了PSVT患者在發作間歇期面臨的生活質量負擔，而星必妥(R)則針對急性發作場景提供了院外應急自救的治療選擇。作為雲頂新耀在心血管疾病領域首個獲批的創新藥物，星必妥(R)將與該公司現有產品布局形成協同效應，未來有望惠及包括PSVT和伴有快速心室率反應的房顫（AFib-RVR）患者在內的超過1,200萬中國患者。